Concho Resources Inc. (CXO) Misled the Investing Public Regarding Optimum Well Spacing and its Ability to Take on Large-Scale Projects   In 2018, Concho constructed the Dominator Project in the

Spectrum Pharmaceuticals, Inc. (SPPI) Materially Misrepresented the Likelihood ROLONTIS Would be Approved by the FDA Spectrum submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”)

Cassava Sciences, Inc. (SAVA) Falsely Touted the Viability and Efficacy of its Lead Drug Candidate     On February 2, 2021, Cassava announced results from its interim analysis of an open-label

HyreCar Inc. (HYRE) Materially Misstated its Insurance Reserves     On May 13, 2021, HyreCar announced “Record First Quarter 2021 Financial Result,” stating that insurance deposits had more than doubled during

Romeo Power, Inc. (RMO, RMO.WT) Misstated its Ability to Meet Demand      On October 5, 2020, RMG Acquisition Corp., a special purpose acquisition company, announced a definitive agreement for a

Cassava Sciences, Inc. (SAVA) Falsely Touted the Viability and Efficacy of its Lead Drug Candidate     On February 2, 2021, Cassava announced results from its interim analysis of an open-label

Zymergen Inc. (ZY) Made Misstatements Regarding its Business Prospects Zymergen held its IPO on April 23, 2021, raising approximately $530.1 million.  On August 3, 2021, Zymergen issued a business update

View, Inc. (VIEW) Misrepresented its Previously Disclosed Warranty Accruals On November 30, 2020, CF Finance Acquisition Corp. II and View announced they had entered into a definitive merger agreement.  On